Metformin Therapy Center

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Study focused on type 2 diabetes patients who initiate metformin.

A low-risk intervention with potentially high rewards.

This study is the first retrospective, long-term analysis of metformin as adjuvant therapy to insulin in patients with T1DM.

Study finds connection between duration of therapy in senior patients and development of neurodegenerative disease.

Study shows age-related comorbidities decreased in males over 65 who take metformin.

Should metformin or glyburide, or a combination of both drugs, be the first-line treatment for gestational diabetes?

Pioglitazone in people with insulin resistance, prediabetes or diabetes is associated with a decreased risk for major adverse cardiovascular events, study data shows.

FDA label update will increase drug use in persons with historical contraindications or precautions.

Meta-analysis found metformin therapy was associated with decreased risk for colorectal adenomas and colorectal cancer among T2 patients.